Keywords: fda, panel, overturns, otc, tagamet, hopes, smithkline
FDA PANEL OVERTURNS OTC TAGAMET HOPES
Article | 20 September 1993
SmithKline Beecham's bid to obtain an over-the-counter status for its histamine H2 receptor antagonist Tagamet (cimetidine) has been blocked by ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
